CTMX - CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer | Benzinga
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.
"Chris has made broad contributions as a member of the CytomX executive team and is a proven cross-functional leader within the organization," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "We are excited to announce this promotion, which is a reflection of Chris' financial acumen, strategic leadership and deep commitment to CytomX's mission."
Mr. Ogden joined CytomX in August of 2021 as Vice President, Finance and Accounting and has since served in roles of increasing responsibility spanning finance, accounting, investor relations, capital raising, information technology, and facilities, most recently as Senior Vice President, Finance and Accounting. Mr. Ogden joined CytomX after a 16-year tenure at Eli Lilly and Company, where he held senior financial leadership positions, including most recently as chief financial officer of Lilly Diabetes. Prior to his role in Lilly Diabetes, Mr. Ogden was the chief financial officer and treasurer of Lilly del Caribe in Puerto Rico. Over the course of his career at Eli Lilly, Mr. Ogden held financial leadership roles that included drug development, manufacturing, commercial operations, and investor relations. Mr. Ogden received his M.B.A. from Harvard Business School and his B.A. in economics from Wabash College.
"It is a privilege to work with the incredibly talented team at CytomX, and I am thrilled to assume the CFO role and to continue to help lead the company through this next chapter, as we pursue our vision to transform lives with safer, more effective cancer therapies," said Chris Ogden. "CytomX's pipeline is positioned in some of the most exciting areas of oncology research and development including T-cell engagers and antibody drug conjugates, and our ...